10 tumour microenvironment Flashcards

1
Q

What is the tumour microenvironment (TME)?

A

he ecosystem surrounding a tumour, consisting of tumour cells, non-tumour cells, and extracellular components.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the three main components of the TME?

A

Tumour cells, non-tumour cells, and the extracellular matrix (ECM).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does the TME support tumour growth?

A

It provides nutrients, survival signals, promotes immune evasion, and facilitates metastasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are five key characteristics of tumour cells?

A

Uncontrolled proliferation, genetic instability, immune evasion, invasion/metastasis, and therapy resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do tumour cells evade the immune system?

A

By downregulating MHC I, secreting immunosuppressive factors, and recruiting pro-tumour immune cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the extracellular matrix (ECM)?

A

A network of proteins like collagen and elastin that provides structural support and stores growth factors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does the ECM contribute to tumour growth?

A

By providing a scaffold for tumour expansion, storing pro-growth signals, and influencing cell behaviour.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the major types of non-tumour cells in the TME?

A

Immune cells, stromal cells, and vascular cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name three types of stromal cells found in the TME.

A

Cancer-associated fibroblasts (CAFs), adipocytes, and pericytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Name three types of vascular cells in the TME.

A

Endothelial cells, lymphatic cells, and pericytes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of endothelial cells in the TME?

A

They support angiogenesis, create abnormal vasculature, and modulate immune responses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do endothelial cells influence metastasis?

A

By forming new blood vessels that allow tumour cells to enter circulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are cancer-associated fibroblasts (CAFs)?

A

Fibroblasts that remodel the ECM, secrete growth factors, and promote tumour invasion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do CAFs contribute to therapy resistance?

A

By modifying the ECM, secreting protective signals, and suppressing immune responses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the two main categories of immune cells in the TME?

A

Anti-tumour (good) and pro-tumour (bad) immune cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name two key anti-tumour immune cells.

A

CD8+ T cells (cytotoxic T cells) and natural killer (NK) cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Name two key pro-tumour immune cells.

A

Neutrophils (PMN-MDSCs) and T regulatory cells (Tregs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How do CD8+ T cells kill tumour cells?

A

By releasing perforin and granzymes or activating death receptors (FasL, TRAIL).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Why are CD8+ T cells important for immunotherapy?

A

They are major targets of immune checkpoint inhibitors that enhance anti-tumour immunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How do NK cells differ from CD8+ T cells?

A

NK cells kill independently of MHC I, making them effective against tumours that downregulate MHC I.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How do neutrophils (PMN-MDSCs) promote tumour growth?

A

By producing ROS and arginase-1, which suppress T cell activity, and by promoting angiogenesis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How do T regulatory cells (Tregs) suppress immune responses?

A

Through immune checkpoints (direct suppression) and cytokine release (indirect suppression).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Why is the composition of the TME important?

A

It influences tumour progression, metastasis, response to therapy, and immune activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the difference between immune hot and cold tumours?

A

Immune hot tumours have active immune responses, while cold tumours lack immune infiltration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is cancer immunoediting?

A

The process by which the immune system interacts with and shapes tumour evolution.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What are the three phases of cancer immunoediting?

A

Elimination, equilibrium, and escape.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What happens during the elimination phase?

A

The immune system detects and destroys transformed cells before a tumour forms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is another name for the elimination phase?

A

Immune surveillance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What happens during the equilibrium phase?

A

The immune system controls tumour growth, but the tumour remains dormant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Why can tumours persist in the equilibrium phase for years?

A

Because of selective immune pressure balancing tumour survival and immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What happens during the escape phase?

A

Tumour cells evolve to evade immune surveillance, leading to rapid tumour progression.

32
Q

How do tumour cells escape immune control?

A

By acquiring mutations, recruiting immunosuppressive cells, and modifying the TME.

33
Q

What is the overall impact of cancer immunoediting?

A

It shapes the tumour microenvironment, influencing tumour survival and immune evasion.

34
Q

How does the TME affect cancer treatment?

A

It impacts immune cell activity, hypoxia, ECM composition, and fibroblast function.

35
Q

Why does hypoxia in the TME reduce treatment efficacy?

A

It decreases drug penetration and promotes therapy resistance.

36
Q

How do CAFs contribute to treatment resistance?

A

By modifying the ECM and secreting survival signals that protect tumour cells.

37
Q

How does the TME promote metastasis?

A

By enhancing tumour cell invasion, angiogenesis, and immune evasion.

38
Q

Why do metastatic tumours have different microenvironments?

A

Because tumour cells adapt to new tissues and interact with local stromal components.

39
Q

What role does angiogenesis play in the TME?

A

It supplies oxygen and nutrients, supporting tumour growth and metastasis.

40
Q

How is tumour vasculature different from normal vasculature?

A

It is abnormal, leaky, and inefficient, contributing to hypoxia and immune evasion.

41
Q

What are the three main components of the TME?

A

Tumour cells, non-tumour cells, and the ECM.

42
Q

How does the TME contribute to immune evasion?

A

By recruiting immunosuppressive cells and downregulating immune signals.

43
Q

What are the three phases of cancer immunoediting?

A

: Elimination, equilibrium, and escape.

44
Q

What is the main function of CD8+ T cells?

A

Killing tumour cells via perforin, granzymes, and death receptors.

45
Q

What type of immune cell is highly immunosuppressive in the TME?

A

T regulatory cells (Tregs).

46
Q

How does ECM influence tumour growth?

A

By providing structural support and storing growth factors.

47
Q

Why are immune hot tumours more responsive to immunotherapy?

A

Because they have more immune cell infiltration.

48
Q

What is the role of pericytes in the TME?

A

Supporting blood vessel stability and function.

49
Q

Why do tumours become resistant to therapy over time

A

Due to genetic mutations, immune evasion, and TME modifications.

50
Q

What are the key functions of the tumour microenvironment (TME)?

A

The TME provides survival signals, facilitates immune evasion, supports metastasis, and influences therapy resistance.

51
Q

How does the TME contribute to immune suppression?

A

By recruiting immunosuppressive cells (e.g., Tregs, MDSCs), secreting inhibitory cytokines, and modifying antigen presentation.

52
Q

Why do tumour cells exhibit genetic instability?

A

Due to accumulated mutations, chromosomal abnormalities, and defective DNA repair mechanisms.

53
Q

How do tumour cells resist therapy?

A

By mutating drug targets, enhancing drug efflux, altering apoptotic pathways, and modifying the TME.

54
Q

How does the ECM store growth factors?

A

It binds and releases growth factors like VEGF and TGF-β, which drive tumour progression.

55
Q

How does ECM remodelling promote tumour invasion?

A

CAFs degrade the ECM using enzymes like MMPs, creating pathways for tumour cells to migrate.

56
Q

What is the role of adipocytes in the TME?

A

They secrete fatty acids and inflammatory cytokines that fuel tumour growth and metastasis.

57
Q

How do pericytes affect tumour vasculature?

A

They stabilize blood vessels but can also promote abnormal angiogenesis in tumours.

58
Q

How does tumour angiogenesis differ from normal angiogenesis

A

Tumour vessels are irregular, leaky, and poorly perfused, contributing to hypoxia.

59
Q

What is the role of VEGF in tumour angiogenesis?

A

VEGF stimulates the growth of new blood vessels, promoting oxygen and nutrient supply to tumours.

60
Q

How do CD8+ T cells recognise tumour cells?

A

They detect tumour antigens presented by MHC class I molecules.

61
Q

What happens when tumour cells downregulate MHC class I?

A

They evade CD8+ T cells but become more vulnerable to NK cell-mediated killing.

62
Q

How do MDSCs suppress T cell function?

A

By producing arginase-1, nitric oxide, and reactive oxygen species (ROS), which inhibit T cell activation.

63
Q

How do tumour-associated macrophages (TAMs) promote tumour growth?

A

They secrete pro-angiogenic factors (e.g., VEGF) and immunosuppressive cytokines (e.g., IL-10, TGF-β).

64
Q

What triggers the elimination phase of cancer immunoediting?

A

The immune system detects transformed cells through tumour antigens and stress signals.

65
Q

What is the role of IFN-γ in the elimination phase?

A

It enhances antigen presentation, activates immune cells, and promotes tumour cell apoptosis.

66
Q

How do tumour cells adapt in the equilibrium phase?

A

They acquire mutations that allow them to resist immune attacks while remaining dormant.

67
Q

What marks the transition from equilibrium to escape?

A

Tumour cells accumulate enough mutations to fully evade immune recognition and suppression.

68
Q

How does hypoxia in the TME affect chemotherapy and radiotherapy?

A

It reduces drug diffusion and makes tumour cells more resistant to radiation-induced DNA damage.

69
Q

Why do cold tumours respond poorly to immunotherapy?

A

They lack immune cell infiltration, reducing the effectiveness of immune checkpoint inhibitors.

70
Q

What role do CAFs play in metastasis?

A

They secrete ECM components and cytokines that help tumour cells invade new tissues.

71
Q

How do tumour cells survive in circulation during metastasis?

A

They form clusters with platelets and immune cells, protecting them from shear stress and immune attack.

72
Q

How do tumour cells exploit immune checkpoints to evade immunity?

A

They upregulate PD-L1, which binds to PD-1 on T cells, inhibiting their activity.

73
Q

What is the function of CTLA-4 in immune suppression?

A

It prevents T cell activation by competing with CD28 for binding to B7 molecules on antigen-presenting cells.

74
Q

What is a key difference between immune hot and cold tumours?

A

Immune hot tumours have high T cell infiltration, while cold tumours lack immune activity.

75
Q

What is a major challenge in targeting the TME for cancer therapy?

A

The TME is highly adaptable and can evolve resistance to treatment.

76
Q

Why is targeting the TME a promising strategy for cancer therapy?

A

Because it affects multiple aspects of tumour progression, from immune evasion to drug resistance.